Information Provided By: 
Fly News Breaks for December 1, 2015
BSX, NVRO
Dec 1, 2015 | 09:01 EDT
JMP Securities increased its price target on Nevro (NVRO) after the U.S. Patent and Trademark Office denied Boston Scientific's (BSX) request for a review of Nevro's U.S. patent. The firm says that the decision "augments the company's value," while its fundamentals "remain excellent." JMP keeps an Outperform rating on Nevro.
News For NVRO;BSX From the Last 2 Days
There are no results for your query NVRO;BSX
